Awareness of, and Compliance with, Domperidone Revised Labeling After a Risk-Minimization Activity in Europe

BACKGROUND AND OBJECTIVE: Risk-minimization measures (RMM), including label revisions were implemented in Europe for domperidone because of evidence of increased incidence of cardiac arrhythmia and sudden cardiac death. In accordance with the guideline on good pharmacovigilance practices, the Europe...

Descripción completa

Detalles Bibliográficos
Autores principales: Fife, Daniel, Waller, John, Kaplan, Sigal, Hu, Peter, Phillips, Syd, Oliveria, Susan A., Richarz, Ute
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2019
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6800405/
https://www.ncbi.nlm.nih.gov/pubmed/31325111
http://dx.doi.org/10.1007/s40261-019-00831-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6800405/
https://www.ncbi.nlm.nih.gov/pubmed/31325111
http://dx.doi.org/10.1007/s40261-019-00831-3

Ejemplares similares